VBIVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:50):

Stats
本日の出来高	219 970
平均出来高	466 877
時価総額	15.79M
EPS	$0 ( 2024-04-01 )
次の収益日	( $-0.530 ) 2024-05-20
Last Dividend	$0.250 ( 2012-04-02 )
Next Dividend	$0 ( N/A )
P/E	-0.0900
ATR14	$0.00600 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-27	Dewilde Michel	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Braga Damian	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Baxter Jeff	Buy	70 000	Option (Right to Buy Common Shares)
2023-07-27	Cordeiro Joanne	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Beattie Nell	Buy	52 500	Option (Right to Buy Common Shares)

INSIDER POWER
-68.18
Last 96 transactions
Buy: 56 847 323 \| Sell: 16 390 901

ボリューム相関

長: -0.23 (neutral)

短: -0.04 (neutral)

Signal:(42.116) Neutral

VBI Vaccines Inc 相関

10 最も正の相関
KRON	0.879
VTSI	0.868
RUBY	0.866
ALVR	0.862
ICCC	0.849
PSTV	0.84
LSBK	0.828
GREE	0.827
POWW	0.827
PAIC	0.826

10 最も負の相関
SHSP	-0.85
NETE	-0.84
BOCH	-0.832
BNIXU	-0.823
RAVN	-0.803

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

VBI Vaccines Inc 相関 - 通貨/商品

-0.20
( neutral )

-0.36
( neutral )

0.00
( neutral )

0.53
( weak )

VBI Vaccines Inc 財務諸表

Annual	2023
収益:	$8.68M
総利益:	$-5.82M (-66.98 %)
EPS:	$-5.96

FY	2023
収益:	$8.68M
総利益:	$-5.82M (-66.98 %)
EPS:	$-5.96

FY	2022
収益:	$1.08M
総利益:	$-10.19M (-942.14 %)
EPS:	$-16.37

FY	2021
収益:	$631 000
総利益:	$-10.14M (-1 606.81 %)
EPS:	$-0.270

Financial Reports:

No articles found.

VBI Vaccines Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

VBI Vaccines Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.250	2003-12-18
Last Dividend	$0.250	2012-04-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.23	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2027-05-31)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.23

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	$0.250	14.60%
2004	$0	0.00%
2005	$0	0.00%
2006	$0.750	16.50%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0.250	0.02%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-11.81	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.179	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-5.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.478	0.800	-2.61	-2.09	[1 - 3]
quickRatioTTM	0.329	0.800	-2.77	-2.21	[0.8 - 2.5]
cashRatioTTM	0.313	1.500	9.37	10.00	[0.2 - 2]
debtRatioTTM	0.610	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-17.68	1.000	-7.66	-7.66	[3 - 30]
operatingCashFlowPerShareTTM	-2.51	2.00	-0.838	-1.676	[0 - 30]
freeCashFlowPerShareTTM	-2.55	2.00	-1.275	-2.55	[0 - 20]
debtEquityRatioTTM	7.05	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	-0.496	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-9.09	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.134	1.000	-7.41	-7.41	[0.2 - 2]
assetTurnoverTTM	0.0998	0.800	-2.67	-2.13	[0.5 - 2]
Total Score				-4.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.134	1.000	-0.115	0	[1 - 100]
returnOnEquityTTM	-5.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.55	2.00	-0.850	-2.55	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-2.51	2.00	-0.838	-1.676	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00180	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-6.93	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.85

VBI Vaccines Inc

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.